September 2005

WADA Prohibited List, 2006
Summary of Major Modifications
SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND
OUT-OF-COMPETITION)
S1. ANABOLIC STEROIDS
The nomenclature of the substances on this list of examples is standardized
as follows:• For substances that have been given an International Non-proprietary
Name (INN), only this name appears.
• Only when the commonly-used name of a substance is better known
than the INN, this commonly-used name appears in parenthesis.
• When the INN is not known, the commonly-used name appears,
accompanied by the International Union of Pure and Applied Chemistry(IUPAC) nomenclature in parenthesis.
1.a. Exogenous Anabolic Steroids•Desoxymethyltestosterone(designersteroid),methasterone,prostanozol and methyl-1-testosterone are added to the list ofexamples.

1.b. Endogenous Anabolic Steroids•The explanatory note in Section 1b: “Endogenous AAS” has beenreworded and expanded in order to further clarify the procedures
and/or tests to follow when an Adverse Analytical Finding is reported
for this category of anabolic androgenic steroids or for a T/E ratio.

•An explanatory paragraph previously included in the Explanatory Noteof the 2005 Prohibited List is added to clarify the procedures for thefollow-up tests after reporting an Adverse Analytical Finding of a very
low concentration of boldenone.

•It is also specified, as described in the Explanatory Note of the 2005
List, that an Adverse Analytical Finding for 19-norandrosterone

1reported by a laboratory is sufficient proof and does not require further
follow-up tests.
Other Anabolic Agents:•Tibolone, a synthetic steroid with anabolic properties used to treat
post-menopausal symptoms, is added to the list of examples.

S.2 HORMONES AND RELATED SUBSTANCES•The status of both human chorionic gonadotrophin (hCG) andluteinizing hormone (LH) is changed and both substances are now only
prohibited in males. Despite the scientific rationale to prohibit thesesubstances in women, the experience during 2005 has led, in somecases, to detect elevated hCG levels due to physiological (pregnancy)
or pathological conditions with potentially significant psychological orsocial consequences for the athlete, in addition to the difficulty, todate, to discriminate at the laboratory level these cases from doping
abuse.

•A paragraph reinforcing the detection of exogenous substances by areliable method is added for consistency with that of endogenous
anabolic steroids in Section 1b.

•“s” is added to “factor” in “insulin-like growth factor” since there ismore than one.

S.3 BETA-2 AGONISTS•The sentence “Their use requires a Therapeutic Use Exemption” in thefirst paragraph is deleted as it applies to all substances on the List andwas deemed redundant with subsequent wording.

•The mention of restricted diagnosis to use of beta-2-agonists byinhalation is deleted in order to be consistent with Section 8 of the
Therapeutic Use Exemption Standard and as it is preferred to leave tothe professional judgment of the physician the medical conditions
under which these drugs have to be prescribed.

•The last paragraph of this section is slightly reworded to stress that aconcentration of salbutamol greater than 1000 ng/mL is considered anadverse analytical finding regardless of the granting of any form of
Therapeutic Use Exemption.

S.5 DIURETICS2•The sentence “Diuretics and other masking agents are prohibited” isremoved as it was deemed redundant with the rest of the paragraph.

•It is clarified that drosperinone, a progestative with mild diuretic
properties, is not prohibited (as indicated in the Explanatory Note ofthe 2005 Prohibited List).

M1. ENHANCEMENT OF OXYGEN TRANSFER•“…other than for medical treatment” is removed from the end ofparagraph “a” as it is deemed unnecessary and ambiguous.

M2. CHEMICAL AND PHYSICAL MANIPULATION•The section is divided into 2 separate subcategories to avoid confusion
between tampering methods used during sample collection andintravenous infusions.

SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION
S.6 STIMULANTS•Adrenaline, which previously was exemplified in a footnote only, is now
clearly named in the list of stimulants.

•Some stimulants considered prohibited but not previously listed as
examples in the 2004 and 2005 List, are re-introduced to the list of
examples for clarification. Therefore cropropamide, crotetamide,etamivan, heptaminol, isometheptene, and the isomers of
methylamphetamine (levmethamfetamine, methamphetamine (D-), pmethylamphetamine,ortetamine,
phenpromethamine,
propylhexedrine) are re-introduced as examples.

•New examples of stimulants are added based on chemical structure orbiological effect(s): cyclazodone, fenbutrazate, meclofenoxate,norfenefrine, octopamine, oxilofrine, pentetrazol, sibutramine.

•Please note that a number of new stimulants added to the section arealso specified substances as indicated in the corresponding section.

S9. GLUCOCORTICOSTEROIDS•

Topical preparations, to treat aural/otic, nasal, buccal cavity andophthalmic ailments, no longer require a Therapeutic Use Exemption

3

due to a wide medical use and the absence of doping potential forthese routes of administration.
SUBSTANCES PROHIBITED IN PARTICULAR SPORTS
P1. ALCOHOL••••FIS requested to be removed from the list of International Federations
testing for alcohol.
Powerboating (UIM) is added with a threshold at 0.30g/L.
International Paralympic Committee (IPC) is added for Archery andBoules (bowls).
FIM requested to change the threshold level from 0.00 g/L to 0.10 g/L.

P2. BETA BLOCKERS•••FINA requested to have prohibition lifted.
IPC is added for Archery, Shooting and Boules (bowls).
The list of different categories of FIS disciplines where beta-blockers
are prohibited is expanded.

SPECIFIED SUBSTANCES
The following stimulants from section S6 are added: cathine, cropropamide,crotetamide,etamivan,
famprofazone,
heptaminol,
isometheptene,meclofenoxate,p-methylamphetamine,nikethamide,norfenefrine,octopamine, ortetamine, oxilofrine, phenpromethamine, propylhexedrine,
selegiline and sibutramine.
MONITORING PROGRAM
The following stimulants from Section S6 will be monitored out-ofcompetition:
adrafinil,
adrenaline,
amfepramone,
amiphenazole,amphetamine, amphetaminil, benzphetamine, bromantan, carphedon,clobenzorex, cocaine, cyclazodone, dimethylamphetamine, etilamphetamine,
etilefrine, fenbutrazate, fencamfamin, fencamine, fenetylline, fenfluramine,
fenproporex,
furfenorex,
mefenorex,
mephentermine,mesocarb,
methamphetamine(D-),
methylenedioxyamphetamine,
methylenedioxymethamphetamine,
methylphenidate,modafinil,
norfenfluramine,parahydroxyamphetamine,
pemoline,
pentetrazol,
phendimetrazine, phenmetrazine, phentermine, prolintane, strychnine.
The monitoring program for in-competition substances will remain as in2005, with the recommendation to extend the number of laboratories

4

participating in this program in order to better monitor some trends observed
for some substances.

5